User login
Key clinical point: Patients with psoriatic arthritis (PsA) who were currently experiencing flares had worse quality of life (QoL), greater disability, and impaired work productivity compared with those who had not experienced flare ever or in the last 12 months.
Major finding: Currently, 168 patients were diagnosed with flare by a physician. Compared with patients who had not experienced flare ever or in the last 12 months, those who were currently experiencing flares had lower QoL scores and higher overall work impairment, disability, and a greater disease impact on patient’s QoL (all P < .01).
Study details: Findings are from the Adelphi PsA Disease Specific Programme, a cross-sectional survey including 2238 patients with PsA and physician-reported flare status data.
Disclosures: The Adelphi SpA IV Disease Specific Programme was funded by Janssen. Two authors declared being employees of Adelphi Real World, and two authors declared being employees of Janssen Pharmaceuticals. The other authors reported receiving research grants and consulting fees from several sources.
Source: Orbai AM et al. Impact of physician-defined flares on quality of life and work impairment: An international survey of 2,238 psoriatic arthritis patients. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.211302
Key clinical point: Patients with psoriatic arthritis (PsA) who were currently experiencing flares had worse quality of life (QoL), greater disability, and impaired work productivity compared with those who had not experienced flare ever or in the last 12 months.
Major finding: Currently, 168 patients were diagnosed with flare by a physician. Compared with patients who had not experienced flare ever or in the last 12 months, those who were currently experiencing flares had lower QoL scores and higher overall work impairment, disability, and a greater disease impact on patient’s QoL (all P < .01).
Study details: Findings are from the Adelphi PsA Disease Specific Programme, a cross-sectional survey including 2238 patients with PsA and physician-reported flare status data.
Disclosures: The Adelphi SpA IV Disease Specific Programme was funded by Janssen. Two authors declared being employees of Adelphi Real World, and two authors declared being employees of Janssen Pharmaceuticals. The other authors reported receiving research grants and consulting fees from several sources.
Source: Orbai AM et al. Impact of physician-defined flares on quality of life and work impairment: An international survey of 2,238 psoriatic arthritis patients. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.211302
Key clinical point: Patients with psoriatic arthritis (PsA) who were currently experiencing flares had worse quality of life (QoL), greater disability, and impaired work productivity compared with those who had not experienced flare ever or in the last 12 months.
Major finding: Currently, 168 patients were diagnosed with flare by a physician. Compared with patients who had not experienced flare ever or in the last 12 months, those who were currently experiencing flares had lower QoL scores and higher overall work impairment, disability, and a greater disease impact on patient’s QoL (all P < .01).
Study details: Findings are from the Adelphi PsA Disease Specific Programme, a cross-sectional survey including 2238 patients with PsA and physician-reported flare status data.
Disclosures: The Adelphi SpA IV Disease Specific Programme was funded by Janssen. Two authors declared being employees of Adelphi Real World, and two authors declared being employees of Janssen Pharmaceuticals. The other authors reported receiving research grants and consulting fees from several sources.
Source: Orbai AM et al. Impact of physician-defined flares on quality of life and work impairment: An international survey of 2,238 psoriatic arthritis patients. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.211302